Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 745,031 |
|
|||||
| News | - | ||||||
| Day High | 27.055 | Low High |
|||||
| Day Low | 25.075 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Arvinas Inc | ARVN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.78 | -2.95% | 25.67 | 17:39:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 26.06 | 25.075 | 27.055 | 25.67 | 26.45 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 12,827 | 745,031 | $ 25.53 | $ 19,022,455 | - | 13.57 - 53.08 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:44:11 | 2 | $ 25.65 | USD |
Arvinas Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.75B | 68.08M | - | 78.5M | -367.3M | -5.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arvinas News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARVN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 27.03 | 28.05 | 25.075 | 26.57 | 638,550 | -1.36 | -5.03% |
| 1 Month | 31.97 | 37.38 | 25.075 | 30.80 | 838,844 | -6.30 | -19.71% |
| 3 Months | 42.93 | 43.07 | 25.075 | 33.17 | 693,434 | -17.26 | -40.20% |
| 6 Months | 35.78 | 53.08 | 25.075 | 39.02 | 751,529 | -10.11 | -28.26% |
| 1 Year | 31.48 | 53.08 | 13.57 | 32.60 | 645,783 | -5.81 | -18.46% |
| 3 Years | 81.92 | 108.465 | 13.57 | 45.87 | 520,419 | -56.25 | -68.66% |
| 5 Years | 19.43 | 108.465 | 13.57 | 46.58 | 504,952 | 6.24 | 32.12% |
Arvinas Description
| Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
